Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity.
Journal: Genes & diseases
Published: July 04, 2017
TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Journal: Breast cancer research and treatment
Published: May 02, 2017
Highlights of the 2015 San Antonio Breast Cancer Symposium.
Journal: Genes & diseases
Published: March 07, 2016
Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.
Journal: Clinical breast cancer
Published: July 30, 2013
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 28, 2013
Showing 1-5 of 5
Last Updated: 09/26/2026